-
Kenya's economy faces climate change risks: World Bank
-
Musk vs OpenAI trial enters second week
-
Japan PM says oil crisis has 'enormous impact' in Asia-Pacific
-
Seoul, Taipei hit records as Asian stocks track Wall St tech rally
-
Boeing faces civil trial over 737 MAX crash
-
Three die on Atlantic cruise ship from suspected hantavirus: WHO
-
Two die in 'respiratory illness' outbreak on Atlantic cruise ship
-
More Nepalis drive electric, evading global fuel shocks
-
Latecomer Japan eyes slice of rising global defence spending
-
German fertiliser makers and farmers struggle with Iran war fallout
-
OPEC+ to make first post-UAE production decision
-
Massive crowds fill Rio's Copacabana beach for Shakira concert
-
US airlines step up as Spirit winds down
-
Aviation companies step up as Spirit winds down
-
'Bookless bookstore': audio-only book shop opens in New York
-
Venezuelan protesters call government wage hike a joke
-
S&P 500, Nasdaq end at fresh records on tech earnings strength
-
Pope names former undocumented migrant as US bishop of West Virginia
-
Trump says will raise US tariffs on EU cars to 25%
-
ExxonMobil CEO sees chance of higher oil prices as earnings dip
-
After Madonna and Lady Gaga, Shakira set for Rio beach mega-gig
-
King Charles gets warm welcome in Bermuda after whirlwind US visit
-
Coe hails IOC gender testing decision
-
Baguettes take centre stage on France's Labour Day
-
Iran offers new proposal amid stalled US peace talks
-
French hub monitors Hormuz tensions from afar
-
Oil steady after wild swing, stocks diverge in thin trading
-
Chinese swimmer Sun Yang reports cyberbullying to police
-
Iran activates air defences as Trump faces congressional deadline
-
India's cows offer biogas alternative to Mideast energy crunch
-
Crude edges up after wild swing, stocks track Wall St rally
-
Formerra Appoints Matt Borowiec as Chief Commercial Officer
-
New Princess Diana documentary promises her own words
-
Oil slumps after hitting peak, US indices reach new records
-
Venezuela leader hikes minimum wage package by 26%
-
Apple earnings beat forecasts on iPhone 17 demand
-
Bangladesh signs biggest-ever plane deal for 14 Boeings
-
Musk grilled on AI profits at OpenAI trial
-
Venezuela opens arms to world with Miami-Caracas flight
-
US Congress votes to end record government shutdown
-
First direct US-Venezuela flight in years arrives in Caracas
-
Just telling nations to quit fossil fuels 'not realistic': COP31 chief
-
Trump hails 'greatest king' Charles as state visit wraps up
-
Drivers help study road-trip mystery: what became of bug splats?
-
Oil strikes 4-year peak, stocks rise
-
Iran's supreme leader defies US blockade as oil prices soar
-
White House against Anthropic expanding Mythos model access: report
-
Oil crisis fuels calls to speed up clean energy transition
-
European rocket blasts off with Amazon internet satellites
-
Nigerian airlines avert shutdown as Mideast war hikes fuel prices
The scientist rewriting DNA, and the future of medicine
A revolution is underway in gene editing -- and at its forefront is David Liu, an American molecular biologist whose pioneering work is rewriting the building blocks of life with unprecedented precision.
A professor at the Broad Institute of MIT and Harvard, Liu was awarded a Breakthrough Prize in Life Sciences on Saturday for developing two transformative technologies: one already improving the lives of patients with severe genetic diseases, the other poised to reshape medicine in the years ahead.
He spoke with AFP ahead of the Los Angeles ceremony for the prestigious Silicon Valley-founded award.
He will receive $3 million for his work on "base editing" and "prime editing," and plans to donate most of it to support his charitable foundation.
"The ability to change a DNA sequence of our choosing into a new sequence of our choosing is a fundamentally very powerful capability," the 51-year-old said, foreseeing uses not just in human medicine but areas like developing more nutritious or disease-resistant crops.
- Correcting the code -
DNA is made up of four chemical "letters" -- the nucleotide bases A, G, T and C. Mutations in this sequence cause thousands of human diseases, yet until recently, gene editing could only fix a limited number of them.
Even CRISPR-Cas9, the groundbreaking technology that earned a Nobel Prize in 2020, has major limitations.
It cuts both strands of the DNA helix, making it most useful to disrupt rather than correct genes, while the process can introduce new errors.
"Being able to use genome editing to treat genetic diseases requires, in most cases, ways to correct a DNA misspelling, not simply to disrupt a gene," Liu said.
That insight led his lab to develop base editing, which uses the Cas9 protein -- disabled so it can no longer cut both DNA strands -- to find a target DNA sequence and another enzyme to convert one letter to another -- for example, C to T or G to A.
Reversing the change -- from T to C or A to G -- was tougher. Liu's team overcame the challenge by engineering entirely new enzymes.
These base editors can now correct about 30 percent of the mutations that cause genetic diseases. The technology is already in at least 14 clinical trials.
In one of them, Beam Therapeutics -- which Liu co-founded -- announced it had treated patients of AATD, a rare genetic disorder affecting the lungs and liver, with a single drug infusion.
While traditional gene therapies often disrupt faulty genes or work around them, base editing repairs the mutation itself.
"This was the first time that humans have corrected a mutation that causes a genetic disease in a patient," Liu said.
- Cystic fibrosis hope -
Base editing, quickly dubbed "CRISPR 2.0," can't fix every mutation.
About 70 percent of the roughly 100,000 known disease-causing mutations remain out of its reach, including those caused by missing or extra letters.
To expand the toolkit, Liu's lab introduced prime editing in 2019 -- a method capable of replacing entire sections of faulty DNA with corrected sequences.
If CRISPR is like scissors that cut DNA, and base editors are like using a pencil to correct individual letters, then prime editing is the equivalent of a word processor's "find and replace" function.
Creating this tool required a series of breakthroughs Liu's team describes as "small miracles." The result is, he said, "the most versatile way we know of to edit the human genome."
Among the targets Liu and his team have already pursued with prime editing: cystic fibrosis, a common genetic disease usually caused by three missing DNA letters that causes thick mucus buildup in the lungs and digestive system.
Liu's lab has made much of its work freely accessible, sharing DNA blueprints through a nonprofit library used by tens of thousands of labs worldwide.
"The science we create -- which is ultimately funded by society, through governments and donors -- ultimately goes back to benefit society."
This year's Breakthrough Prize awards come at a fraught moment for US science, as President Donald Trump's government strips funding for institutions like the National Institutes of Health (NIH).
"The NIH is a treasure, not just for this country but for the world," said Liu. "Trying to dismantle the heart of what supports science in this country is like burning your seed corn."
Y.Uduike--CPN